ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT)
Health Care · biotechnology · NASDAQ
Arcturus Therapeutics is a clinical-stage mRNA company developing liver and respiratory disease therapeutics powered by its proprietary self-amplifying mRNA and lipid nanoparticle delivery platforms.
What ARCTURUS THERAPEUTICS HOLDINGS INC does
Arcturus Therapeutics is a clinical-stage biotechnology company focused on the development of messenger RNA (mRNA) medicines for liver and respiratory rare diseases. The company utilizes its proprietary STARR self-amplifying mRNA platform and LUNAR lipid nanoparticle delivery system to develop therapeutics and vaccines. Its lead programs include ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase (OTC) deficiency.
Recent developments
Arcturus regained global rights to its KOSTAIVE vaccine and infectious disease portfolio after terminating its collaboration with CSL Seqirus. The company also entered into a strategic collaboration with Thermo Fisher Scientific for CDMO and CRO services to support the Phase 3 development of its cystic fibrosis candidate, ARCT-032.
From ARCTURUS THERAPEUTICS HOLDINGS INC's filing of 2026-08-06.
Themes: mRNA therapeutics, rare diseases, cystic fibrosis, LNP delivery platforms, vaccine development
Fundamentals
- Price$12.87 as of 2026-10-08 close
- Market cap$366M as of 2026-08-04 (share count; price 2026-10-08)
- 1-year return-39.3% 2025-10-08 close $21.20 → 2026-10-08 close $12.87
- P/En/a negative earnings
- Net margin-80.2% FY2025, SEC XBRL
- ROE-30.7% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)-76.0% as of 2026-09-03
- Revenue CAGR (3y)-26.4% SEC XBRL
- Beta1.50 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How ARCT compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ARCTURUS THERAPEUTICS HOLDINGS INC looks technically
ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) is trading 49.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 31 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 46.8% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 49.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +49.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $12.39 | $12.39 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $8.62 | $8.62 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 17.96. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 31 trading days ago — a "golden cross", a bullish long-term signal | 31 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 49.3% above | +49.3% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) | 23.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30) | 45.7 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($12.03 to $16.55) — its "stochastic" reading is 19 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 18.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 22 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $24.17 | $24.17 |
|---|---|---|
| From the 52-week high | it is 46.8% below its 52-week high (its highest price of the past year) | -46.8% |
| Above the 52-week low | it is 134.0% above its 52-week low (its lowest price of the past year) | +134.0% |
| Below the 52-week high | it is 46.8% below its highest point of the past year | 46.8% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 16 trading days ago | 16 sessions |
| All-time high | its highest closing price on record is $188.53 (set on 2013-10-04) | $188.53 |
| Given back of the 52-week move | over the past year its closes ranged ($5.53 to $23.16), and it has recovered roughly a third of its fall from last year’s high — 42% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $16.43 to $16.99. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 41.6% |
| From the all-time high | it is 93.2% below its all-time high | -93.2% |
| Nearest price level | it is trading 0.9% above a support level at $12.75 — a price it turned at twice since 2025-03-11, most recently on 2025-07-15. Since 2024-10-08 it has 6 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.9% |
| All-time low | its lowest closing price on record is $4.11 (set on 2018-12-28) | $4.11 |
| Above the all-time low | it is 213.1% above its all-time low | +213.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 53rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.28 between its high and its low — about 10.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.28 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $12.01 and $16.60 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $12.01 – $14.31 – $16.60 |
| Typical daily range (% of price) | its price moves about 10.0% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 10.0% |
| Stretch from the 200-day average | it is trading 3.3 daily ranges above its 200-day average price (49.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.70× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 2.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -2.5% |
|---|---|---|
| Open gap | it gapped 14.6% above the previous close 35 sessions ago and has not traded back through the level it left behind at 8.21 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +14.6% |
| Gap filled | a 2.5% gap down opened on 2026-10-08 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened it | today |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 18.7 percentage points (the stock lost 17.7% while the market gained 1.0%) | -18.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 72.5 percentage points (the stock gained 76.3% while the market gained 3.8%) | +72.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 39.1 percentage points (the stock gained 56.6% while the market gained 17.5%) | +39.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 54.3 percentage points (the stock lost 39.3% while the market gained 15.0%) | -54.3% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold), trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 4.4% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 9.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +4.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 30% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $9.91 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +29.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $13.29 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -3.1% |
Price levels it has turned at before
ARCT last closed at $12.87 on 2026-10-08. Since 2024-10-08 it has turned at 6 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $12.75 | Support | 0.9% below the last close | turned there twice · 2025-03-11 to 2025-07-15 |
| $13.06 | Resistance | 1.5% above the last close | turned there twice · 2025-05-22 to 2026-09-10 |
| $13.63 | Resistance | 5.9% above the last close | turned there three times · 2025-04-23 to 2025-06-10 |
| $14.84 | Resistance | 15.3% above the last close | turned there twice · 2024-11-15 to 2025-06-26 |
| $9.19 | Support | 28.6% below the last close | turned there twice · 2025-10-22 to 2026-04-17 |
| $8.04 | Support | 37.5% below the last close | turned there twice · 2025-04-07 to 2026-05-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $17.96.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 11 trading days, since 2026-09-24.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke down to a new 20-day low · beating the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.38 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$23.20 range $9.00 – $41.00; median $20.00
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ARCT
- Consensus EPS estimate-$0.6704 next reporting period, as of 2026-10-05
- Estimate change, 30 days$0.00 from -$0.6704, on 2026-09-01, 34-day window
- Readings revised upward0% of 5 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant history of losses and expected continued unprofitability during clinical development.","Heavy reliance on third-party collaborations and manufacturing partners for late-stage development and commercialization.","Clinical trial results for novel sa-mRNA and LNP technologies may fail to demonstrate required safety or efficacy."]
What changed in the latest 10-Q
AI-assisted comparison of ARCT's 10-Q filed 2026-08-06 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-06) states the discussion covers 'the three and six months ended June 30, 2026', while older filing (2026-05-07) stated it covered 'the three-month period ended March 31, 2026'.
- Newer filing adds a new section titled 'Thermo Fisher Agreement' describing agreements entered into on June 26, 2026 with Thermo Fisher Scientific Inc. and affiliates, including a Master Services Agreement and a Project Agreement, for CDMO and CRO services related to ARCT-032 development.
- Newer filing states the fourth cohort of the ARCT-032 Phase 2 study 'continues to advance with active screening and enrollment in the United States and Israel'.
- Newer filing states all enrolled subjects in the ARCT-810 Phase 2 study 'have completed study drug dosing' and the company continues to evaluate supplementary data to inform regulatory discussions and an End-of-Phase 2 meeting.
- Newer filing states the company 'regained strategic control of KOSTAIVE and our broader vaccine portfolio, subject to ongoing arrangements with Meiji in Japan for the Northern Hemisphere 2026-2027 season'.
- Removed:
- Older filing (2026-05-07) stated KOSTAIVE was 'partnered with Seqirus, Inc. ("CSL Seqirus"), a part of CSL Limited'.
- Older filing included a section on the 'Vaccine Collaboration with CSL Seqirus' describing the November 2022 Collaboration and License Agreement with Seqirus, Inc. for global exclusive rights to COVID-19, influenza, and other infectious disease vaccines.
- Older filing stated the company 'continue[s] to enroll participants' in the ARCT-810 Phase 2 study.
- Older filing included a paragraph about a March 2026 type C meeting with the FDA regarding a proposed future pediatric study for ARCT-810.
- Older filing included sections titled 'Marketing Authorization Application filing of KOSTAIVE in United Kingdom' and a paragraph beginning 'In CSL Limited's half-year results presented on February 11, 2026...' describing the MHRA marketing authorization and CSL Limited's accounting write-down.
- Reworded:
- Overview: Older filing said the company 'partnered with Seqirus, Inc.' for KOSTAIVE; newer filing removed that partnership reference and instead stated the company 'regained strategic control' of the vaccine.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for ARCT — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding ARCT as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 6,208,079
- Reported value $41,718,292
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ARCT's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ARCT had 5,467,974 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ARCT had 19.2% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.37 days to cover at the same settlement.
- Reported short interest (shares) 5,467,974
- Short interest (% of shares outstanding) 19.2%
- Prior settlement (shares) 6,096,901
- Reported change -10.32%
- Days to cover (reported) 6.37
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Moderna (MRNA)
- BioNTech (BNTX)
- CureVac (CVAC)
- Vertex Pharmaceuticals (VRTX)
- Translate Bio (Sanofi)
- Alnylam Pharmaceuticals (ALNY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ARCT vs…
ARCTURUS THERAPEUTICS HOLDINGS INC is found in…
Frequently asked questions
What does ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) do?
Arcturus Therapeutics is a clinical-stage biotechnology company focused on the development of messenger RNA (mRNA) medicines for liver and respiratory rare diseases. The company utilizes its proprietary STARR self-amplifying mRNA platform and LUNAR lipid nanoparticle delivery system to develop therapeutics and vaccines. Its lead programs include ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase (OTC) deficiency.
What sector is ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) in?
ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are ARCTURUS THERAPEUTICS HOLDINGS INC's (ARCT) competitors?
Notable peers of ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) include Moderna, BioNTech, CureVac, Vertex Pharmaceuticals and Translate Bio (Sanofi). This peer set is informational only — not financial advice.
Is ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) overbought or oversold right now?
ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 46, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ARCT come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.